These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20371423)

  • 1. [Implications of receptors for the Fc portion of IgG (FcgammaRs) in mechanism of action of therapeutic antibodies].
    Lejeune J; Thibault G; Cartron G; Ohresser M; Watier H
    Bull Cancer; 2010 May; 97(5):511-22. PubMed ID: 20371423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
    Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
    Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
    Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
    Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
    Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
    Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective.
    Desjarlais JR; Lazar GA; Zhukovsky EA; Chu SY
    Drug Discov Today; 2007 Nov; 12(21-22):898-910. PubMed ID: 17993407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of FcγRs in Antibody-Based Cancer Therapy.
    Graziano RF; Engelhardt JJ
    Curr Top Microbiol Immunol; 2019; 423():13-34. PubMed ID: 30790079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
    Clynes RA; Towers TL; Presta LG; Ravetch JV
    Nat Med; 2000 Apr; 6(4):443-6. PubMed ID: 10742152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harnessing the immune system via FcγR function in immune therapy: a pathway to next-gen mAbs.
    Chenoweth AM; Wines BD; Anania JC; Mark Hogarth P
    Immunol Cell Biol; 2020 Apr; 98(4):287-304. PubMed ID: 32157732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies.
    Iannello A; Ahmad A
    Cancer Metastasis Rev; 2005 Dec; 24(4):487-99. PubMed ID: 16408158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The FcγR of humans and non-human primates and their interaction with IgG: implications for induction of inflammation, resistance to infection and the use of therapeutic monoclonal antibodies.
    Hogarth PM; Anania JC; Wines BD
    Curr Top Microbiol Immunol; 2014; 382():321-52. PubMed ID: 25116107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FcgammaR: The key to optimize therapeutic antibodies?
    Sibéril S; Dutertre CA; Fridman WH; Teillaud JL
    Crit Rev Oncol Hematol; 2007 Apr; 62(1):26-33. PubMed ID: 17240158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant therapeutic monoclonal antibodies: mechanisms of action in relation to structural and functional duality.
    Congy-Jolivet N; Probst A; Watier H; Thibault G
    Crit Rev Oncol Hematol; 2007 Dec; 64(3):226-33. PubMed ID: 17716905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights into the role of Fc gamma receptors (FcgammaRs) genetic variations in monoclonal antibody-based anti-cancer therapy.
    Concetti F; Napolioni V
    Recent Pat Anticancer Drug Discov; 2010 Nov; 5(3):197-204. PubMed ID: 20594185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer.
    Green SK; Karlsson MC; Ravetch JV; Kerbel RS
    Cancer Res; 2002 Dec; 62(23):6891-900. PubMed ID: 12460904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities.
    Nimmerjahn F; Gordan S; Lux A
    Trends Immunol; 2015 Jun; 36(6):325-36. PubMed ID: 25981969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting FcγRs to treat antibody-dependent autoimmunity.
    Yu X; Lazarus AH
    Autoimmun Rev; 2016 Jun; 15(6):510-2. PubMed ID: 26854400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Cell-Based Reporter Assay Measuring the Activation of Fc Gamma Receptors Induced by Therapeutic Monoclonal Antibodies.
    Aoyama M; Tada M; Ishii-Watabe A
    Methods Mol Biol; 2019; 1904():423-429. PubMed ID: 30539484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases.
    Chan KR; Ong EZ; Mok DZ; Ooi EE
    Expert Rev Anti Infect Ther; 2015; 13(11):1351-60. PubMed ID: 26466016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy.
    Hubert P; Heitzmann A; Viel S; Nicolas A; Sastre-Garau X; Oppezzo P; Pritsch O; Osinaga E; Amigorena S
    Cancer Res; 2011 Aug; 71(15):5134-43. PubMed ID: 21697279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.